ARTICLE
14 August 2015

FDA Sends Warning Letter For Kim Kardashian's Instagram Post

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
On Mintz Levin's Health Law and Policy Matters blog, our colleague Joanne Hawana discussed the August 7 Warning Letter sent by FDA to the drug company Duchesnay, Inc...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On Mintz Levin's Health Law and Policy Matters blog, our colleague Joanne Hawana discussed the August 7 Warning Letter sent by FDA to the drug company Duchesnay, Inc., after Kim Kardashian praised the company's morning sickness pill Diclegis in an Instagram post.

As described in the blog post, FDA objected to Kardashian's social media post and called it false and misleading because the post failed to include information on significant limitations of the drug, as well as warnings and precautions. Because Kardashian is a paid spokesperson for Diclegis, her Instagram post promoting the drug must follow the same rules as other consumer advertisements for prescription drugs. The social media post was taken down immediately after Duchesnay received the Warning Letter. Read more about it here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
14 August 2015

FDA Sends Warning Letter For Kim Kardashian's Instagram Post

United States Food, Drugs, Healthcare, Life Sciences

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More